|18.07 0.07 (0.39%)||12-08 16:00|
|Targets||6-month :||21.65||1-year :||25.29|
|Resists||First :||18.54||Second :||21.65|
|Supports||First :||15.22||Second :||13.18|
|MAs||MA(5) :||17.95||MA(20) :||16.27|
|MA(100) :||15.54||MA(250) :||14.49|
|MACD||MACD :||1||Signal :||0.9|
|%K %D||K(14,3) :||89.3||D(3) :||88.3|
|52-week||High :||18.54||Low :||11.39|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AORT ] has closed below upper band by 31.7%. Bollinger Bands are 104% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||18.57 - 18.64||18.64 - 18.72|
|Low:||17.78 - 17.86||17.86 - 17.93|
|Close:||17.94 - 18.08||18.08 - 18.21|
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Tue, 21 Nov 2023
How To Trade Artivion Inc Com $AORT - Stock Traders Daily
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||41 (M)|
|Shares Float||37 (M)|
|Held by Insiders||4.5 (%)|
|Held by Institutions||86.8 (%)|
|Shares Short||3,000 (K)|
|Shares Short P.Month||2,560 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||6.61|
|Profit Margin||-7.3 %|
|Operating Margin||5.6 %|
|Return on Assets (ttm)||0.8 %|
|Return on Equity (ttm)||-9.4 %|
|Qtrly Rev. Growth||14.3 %|
|Gross Profit (p.s.)||4.93|
|Sales Per Share||8.27|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||8 (M)|
|Levered Free Cash Flow||8 (M)|
|Price to Book value||2.72|
|Price to Sales||2.18|
|Price to Cash Flow||95.46|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|